Clinical Trials Directory

Trials / Conditions / Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

12 registered clinical trials studyying Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Anti
NCT07526493
Tongji HospitalPhase 1
RecruitingCD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
NCT07337785
Daishi TianEARLY_Phase 1
Not Yet RecruitingRipertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
NCT06858722
Zhongming QiuPhase 3
RecruitingStudying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
NCT07461896
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta—
RecruitingPolyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
NCT06040567
Rigshospitalet, Denmark—
CompletedComparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP.
NCT05492604
University Hospital, BordeauxN/A
Active Not RecruitingA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults Wi
NCT04280718
argenxPhase 2
CompletedA Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic
NCT04281472
argenxPhase 2
UnknownPanzyga in CIDP Administered at Different Infusion Rates
NCT03166527
Vera BrilPhase 3
CompletedExtension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory D
NCT02027701
CSL BehringPhase 3
No Longer AvailableCIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
NCT05014724
UCB Biopharma SRL—
AvailablePre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
NCT04777734
argenx—